Capricor Therapeutics Inc. (CAPR)

Profile

https://www.capricor.com

Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases with high unmet medical need. The company concentrates particularly on Duchenne muscular dystrophy, targeting both skeletal and cardiac muscle complications associated with this progressive disorder. Capricor’s lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy being evaluated in late-stage clinical trials for Duchenne muscular dystrophy, supported by multiple Phase 3 and long-term extension studies. Beyond Deramiocel, Capricor is advancing a pipeline of exosome-based candidates aimed at leveraging engineered extracellular vesicles as delivery platforms in severe and difficult-to-treat conditions. Headquartered in San Diego, California, Capricor operates within the biotechnology and medical research segment of the healthcare sector, engaging with regulators, clinicians, and patient communities to bring advanced biological therapies toward potential commercialization. Through its specialized focus on rare neuromuscular and related diseases, the company plays a distinct role in the emerging field of regenerative and cell-based medicine.